AstraZeneca’s GLP-1 Pill Shows Early Promise in Obesity & Diabetes Trials-How It Compares to Ozempic & Lilly’s Foundayo
AstraZeneca’s GLP-1 Pill Shows Early Promise in Obesity and Diabetes Trials On June 8, 2026, AstraZeneca’s investigational GLP-1 pill, elecoglipron, demonstrated significant weight loss and blood sugar reduction in mid-stage ... Read More